---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-177433"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:29:52.717373+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# First patient dosed in Phase 3 EMPEROR study of zorevunersen for Dravet syndrome by Stoke and Biogen

## Summary
- First patient dosed in global Phase 3 EMPEROR study of zorevunersen for Dravet syndrome.
- Randomized 1:1 vs sham over 52 weeks; primary endpoint: change in major motor seizure frequency at Week 28.
- Zorevunersen is an investigational antisense oligonucleotide; potential first disease-modifying treatment for Dravet syndrome.
- Key secondary endpoints include cognition/behavior via Vineland-3 subdomains at Week 52.
- Enrollment: ages 2-18 with SCN1A mutation; open-label extension offered to eligible participants.

## SEC filing metadata
- accession: 0001193125-25-177433
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312525177433/0001193125-25-177433-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312525177433/d64221d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-177433
- JSON: https://secwatch.observer/filing/0001193125-25-177433.json
- Plain text: https://secwatch.observer/filing/0001193125-25-177433.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.